长期严重的缺氧适应会诱导非正规的EMT和一种新的威尔姆斯瘤1 (WT1) 异型
Jordan Quenneville1,2, Albert Feghaly3, Margaux Tual3,4
1Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada. jquennev@gmail.com.
Cancer gene therapy
|July 8, 2024
概括
研究人员发现了一种新的WT1蛋白异型 (tWt1),在低氧条件下驱动癌细胞变化. 这一发现在长期缺氧培养物中观察到,与患者的生存率差相关,突出了固体瘤中的新治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 固体瘤导致大多数癌症死亡,异质性是由微环境驱动的,如缺氧影响治疗.
- 了解瘤微环境对于改善流行癌症的治疗结果至关重要.
研究的目的:
- 开发一种新的培养方法,长期缺氧 (LTHY) 时间过程,模仿体内瘤缺氧.
- 研究参与瘤适应缺氧的分子机制,包括新型蛋白质异型.
- 为了确定预测患者在低氧癌症条件下生存的生物标志物.
主要方法:
- 开发并使用长期缺氧 (LTHY) 培养方案来模拟逐渐严重的缺氧.
- 使用miRNA和mRNA签名分析了细胞变化,包括表皮转变为介质细胞 (EMT),使用miRNA和mRNA签名.
- 鉴定和表征了一种新的截断WT1异型 (tWt1) 和其调节元件 (低氧反应元件).
- 在LTHY培养细胞系和人类原发性癌症中评估tWt1表达.
主要成果:
- 用LTHY培养的细胞表现出非正规的上皮细胞转移到介质细胞转变 (EMT),具有特征性的形态和分子变化.
- 确定了一种新的截断的WT1异型 (tWt1),由通过低氧反应元素的内基促进体驱动.
- tWt1从内部衍生的起始编码子开始翻译,保持亚细胞局部化,并保持DNA结合能力.
- 在LTHY培养的人类癌细胞系和原发性癌症中发现了类似的tWt1表达,与患者的长期存活率差,特别是卵巢癌相关.
结论:
- 模仿体内瘤缺氧的培养条件对于精确的癌症研究至关重要.
- 一种新的WT1异型 (tWt1) 在低氧压力下充当非正规的EMT驱动器.
- tWt1表达是一种潜在的预后生物标志物,用于各种癌症,特别是卵巢癌的长期生存.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
02:54Canonical Wnt Signaling Pathway
8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:41Non-Canonical Wnt Signaling Pathways
7.3K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K